6-K - CYBIN INC. (0001833141) (Filer)

6-K - CYBIN INC. (0001833141) (Filer)

6-K - CYBIN INC. (0001833141) (Filer)

6-K - CYBIN INC. (0001833141) (Filer)

6-K - CYBIN INC. (0001833141) (Filer)

SCHEDULE 13G - CYBIN INC. (0001833141) (Subject)

6-K - CYBIN INC. (0001833141) (Filer)

SCHEDULE 13G/A - CYBIN INC. (0001833141) (Subject)

6-K - CYBIN INC. (0001833141) (Filer)

6-K - CYBIN INC. (0001833141) (Filer)

Jefferies initiated coverage of Helus Pharma with a rating of Buy and set a new price target of $22.00

Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma's continued maturation as the company advances its novel clinical pipeline NEW YORK and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the appointment of Jill Conwell as Chief People Officer, effective immediately. Conwell brings more than two decades of leadership experience in the life sciences industry, with expertise spanning organizational st

Issued on behalf of Cybin D/B/A Helus PharmaUSANewsGroup.com News CommentaryVANCOUVER, BC, March 9, 2026 /CNW/ -- The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials and regulatory milestones accumulate1. The Drug Enforcement Administration raised its 2026 production quotas for controlled research compounds by 67%, reflecting expanding clinical trial activity across the therapeutics landscape2. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), a

GAD Therapies Market Set to Explode to $4.26B by 2033 as Demand Rockets for Innovative Anxiety Solutions NEW YORK, March 5, 2026 /CNW/ -- Market News Updates News Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news for millions of people dealing with constant worry and stress. Traditional medications like anti-anxiety drugs and antidepressants still play a big role, but therapy options such as cognitive-behavioral therapy and mindfulness techniques are also helping people manage symptoms without relying only on medication. Digital mental health tools and telehealth visits are making treatment easier to access, especially f

Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale ("HAM-A") of ~10 points on top of Standard of Care ("SoC") at 6 weeksDurable effects sustained through at least 6 monthsIn Phase 1 trial most participants were ready for discharge within 3 hours1; Acute effects lasted ~90 minutesGenerally well-tolerated, adverse events were transient, with no drug related serious adverse events recordedAt six months, the pooled study population showed 67% responders and 39% of patients were in remission (see Figure 1 below) Figure 1 This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement date

Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus Pharma (NASDAQ:HELP), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), GH Research (NASDAQ:GHRS), and LB Pharmaceuticals (NASDAQ:LBRX).

Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 26, 2026 /CNW/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that milestone this week, signaling a potential shift in how regulators and investors view psychedelic-based psychiatry[1]. The pathway is widening at the federal level, where the Drug Enforcement Administration raised its 2026 psilocybin production quota by 67%[2]. Five companies are working to translate that momentum into approved treatments: Helus Pharma (NASDAQ:HELP), Compass Pathways (NASDAQ:CMPS), Relmada Therapeutics (NASDAQ:RLMD), Alto Neuroscience (NYSE:ANRO), and Axsome

In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus' novel serotonergic agonist ("NSA") portfolio This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company developing NSAs for serious mental health conditions, today announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its Board of Di

Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive symptoms as measured by MADRS score (mean difference: -7.35) versus placebo at two weeksAntidepressant treatment effects observed within one week and sustained for up to three months Findings reinforce the therapeutic potential of short-acting serotonergic agonists and inform Helus Pharma's HLP004 development program, with Phase 2 topline data in generalized anxiety disorder ("GAD") expected in Q1 2026 This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short

- Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events -- Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder ("GAD") expected in Q1 2026 - This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. BOSTON and TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- HELUS PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today re

Former President of Shire PLC's ("Shire") Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLCProven leader in late-stage clinical development, global commercialization, and capital formation across central nervous system ("CNS") programsAppointed as Helus Pharma advances its pipeline toward key clinical milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 later this year This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated

Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma's continued maturation as the company advances its novel clinical pipeline NEW YORK and TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Helus PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today announced the appointment of Jill Conwell as Chief People Officer, effective immediately. Conwell brings more than two decades of leadership experience in the life sciences industry, with expertise spanning organizational st

In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus' novel serotonergic agonist ("NSA") portfolio This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company developing NSAs for serious mental health conditions, today announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its Board of Di

- Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events -- Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder ("GAD") expected in Q1 2026 - This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. BOSTON and TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- HELUS PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today re

Former President of Shire PLC's ("Shire") Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLCProven leader in late-stage clinical development, global commercialization, and capital formation across central nervous system ("CNS") programsAppointed as Helus Pharma advances its pipeline toward key clinical milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 later this year This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated